Gilead Sciences has made another foray into the natural killer (NK) cell category, paying $300 million upfront to access Dragonfly Therapeutics' TriNKET platform to find therapies for cancer and ...
Bristol-Myers Squibb has signed an agreement worth $475 million to develop a new form of cancer immunotherapy drug with US biotech Dragonfly Therapeutics. BMS is best known as an early pioneer of ...
Lead optimization is the process by which a drug candidate is designed after an initial lead compound is identified. The process involves iterative rounds of synthesis and characterisation of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback